Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.38 |
| ▸ | PRKCG | P05129 | 2/20 | 0.38 |
| ▸ | PRKCB | P05771 | 2/20 | 0.38 |
| ▸ | PRKCA | P17252 | 2/20 | 0.38 |
| ▸ | PRKCH | P24723 | 2/20 | 0.38 |
| ▸ | PRKCI | P41743 | 2/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 11/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16841232 | 0.88 | ALDH1A1 (0.61) | ALDH1A1EPHX1PRKD3PRKCGPRKCB | |
| SCHEMBL25850990 | 0.77 | ALDH1A1 (0.48) | ALDH1A1EPHX1PRKD3PRKCGPRKCB | |
| SCHEMBL6554483 | 0.75 | ALDH1A1 (0.46) | ALDH1A1EPHX1PRKD3PRKCGPRKCB | |
| SCHEMBL18624135 | 0.74 | ALDH1A1 (0.39) | ALDH1A1EPHX1 | |
| SCHEMBL16829849 | 0.74 | ALOX5 (0.57) | ALDH1A1 | |
| SCHEMBL18195607 | 0.73 | ALDH1A1 (0.48) | ALDH1A1EPHX1PRKD3PRKCGPRKCB | |
| SCHEMBL12158821 | 0.72 | ALDH1A1 (0.54) | ALDH1A1EPHX1 | |
| SCHEMBL11263375 | 0.71 | ALDH1A1 (0.56) | ALDH1A1EPHX1PRKD3PRKCGPRKCB | |
| SCHEMBL11270485 | 0.71 | ALDH1A1 (0.56) | ALDH1A1EPHX1PRKD3PRKCGPRKCB | |
| SCHEMBL7136174 | 0.71 | ALDH1A1 (0.72) | ALDH1A1EPHX1PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230058784-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20210078936-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885EPHX1 4437/4885PRKD3 3037/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | ALDH1A1 2999/4885EPHX1 4063/4885PRKD3 2811/4885 |
| US-20210078936-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LPAR1, LPAR4, LIPA | ALDH1A1 1777/4885EPHX1 588/4885PRKD3 3843/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885EPHX1 4437/4885PRKD3 3037/4885 |
| US-20230058784-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, RNGTT, HNRNPAB | ALDH1A1 4532/4885EPHX1 4605/4885PRKD3 2348/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885EPHX1 4437/4885PRKD3 3037/4885 |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | PHOSPHO1, SGMS1, ABCB4 | ALDH1A1 2414/4885EPHX1 929/4885PRKD3 3410/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | ALDH1A1 4532/4885EPHX1 4605/4885PRKD3 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.